The New England Journal of Medicine November 20, 2008

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein (JUPITER)

Paul M. Ridker, Eleanor Danielson, Francisco A.H. Fonseca et al.

Bottom Line

In apparently healthy individuals with normal LDL cholesterol but elevated high-sensitivity C-reactive protein, rosuvastatin significantly reduced the incidence of major cardiovascular events compared to placebo.

Key Findings

1. The trial was stopped early after a median follow-up of 1.9 years (maximum 5.0) due to crossing the prespecified efficacy boundaries.

2. Rosuvastatin 20 mg daily reduced LDL cholesterol levels by 50% (median 108 to 55 mg/dL) and high-sensitivity C-reactive protein (hsCRP) levels by 37%.

3. The primary composite endpoint occurred at a rate of 0.77 vs 1.36 per 100 person-years in the rosuvastatin and placebo groups, respectively (HR 0.56; 95% CI 0.46-0.69; P<0.00001).

4. Rosuvastatin significantly reduced rates of myocardial infarction (0.17 vs 0.37 per 100 person-years; HR 0.46; P=0.0002) and stroke (0.18 vs 0.34 per 100 person-years; HR 0.52; P=0.002).

5. Rates of arterial revascularization or unstable angina were also significantly lower (0.41 vs 0.77 per 100 person-years; HR 0.53; P<0.00001).

6. All-cause mortality was significantly reduced in the rosuvastatin group (1.00 vs 1.25 per 100 person-years; HR 0.80; 95% CI 0.67-0.97; P=0.02).

7. There was a small but statistically significant increase in physician-reported incident diabetes in the rosuvastatin arm (270 vs 216 cases; P=0.01).

Study Design

Design

Randomized Controlled Trial

Double-Blind

Sample

17,802

Patients

Duration

1.9 yr

Median

Setting

Multinational (26 countries)

Population Apparently healthy men (≥50 years) and women (≥60 years) without clinical cardiovascular disease or diabetes, with LDL cholesterol <130 mg/dL (3.4 mmol/L) and hsCRP ≥2.0 mg/L.

Intervention Rosuvastatin 20 mg daily

Comparator Matching placebo

Outcome First occurrence of the combined endpoint of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes.

Study Limitations

• The trial was terminated early (at 1.9 years rather than the planned duration), which can sometimes lead to an overestimation of the magnitude of the treatment effect.

• Because rosuvastatin profoundly lowered both LDL-C and hsCRP, the trial could not definitively isolate whether the clinical benefit was driven primarily by lipid lowering to unprecedentedly low levels or by pleiotropic anti-inflammatory effects.

• The findings do not directly establish the utility of hsCRP screening or statin therapy for individuals with hsCRP < 2.0 mg/L, nor do they apply to younger patients (men < 50, women < 60 years of age).

• The small absolute increase in incident diabetes highlights the need for careful risk-benefit assessments, particularly in lower-risk primary prevention populations.

Clinical Significance

JUPITER established that a simple biomarker of systemic inflammation (hsCRP) could identify individuals at high risk for cardiovascular events despite having 'normal' or 'low' LDL cholesterol levels. It demonstrated that potent statin therapy in this targeted population yields dramatic reductions in cardiovascular morbidity and all-cause mortality, fundamentally shifting primary prevention paradigms to incorporate inflammation into cardiovascular risk assessment.

Historical Context

Prior to JUPITER, statin therapy was largely restricted to patients with established cardiovascular disease, diabetes, or overtly elevated LDL cholesterol. However, epidemiological data consistently showed that nearly half of all cardiovascular events occurred in patients with normal or low LDL cholesterol. Based on prior observations that elevated hsCRP independently predicted cardiovascular risk, JUPITER was designed to test the inflammatory hypothesis of atherothrombosis. Its landmark results influenced major international lipid guidelines, leading to the incorporation of hsCRP as a 'risk-enhancing' factor in primary prevention algorithms.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How do statins lower cholesterol, and what is the biological significance of using high-sensitivity C-reactive protein (hsCRP) as an inclusion criterion in this trial instead of solely relying on LDL levels?

Key Response

Statins inhibit HMG-CoA reductase, decreasing hepatic cholesterol synthesis and upregulating LDL receptors. hsCRP is a marker of systemic inflammation, which is a key driver of atherosclerosis. JUPITER highlights statins pleiotropic anti-inflammatory effects and the role of inflammation in CV risk among patients with normal LDL.

Resident

A 55-year-old male with an LDL of 115 mg/dL and hsCRP of 2.5 mg/L asks if he should start a statin based on the JUPITER trial. What are the key clinical benefits to discuss, and what specific adverse effect noted in the trial should be monitored?

Key Response

Based on JUPITER, the patient meets criteria for primary prevention with rosuvastatin, which significantly reduces the risk of major CV events. However, residents must be aware of the increased incidence of physician-reported incident diabetes mellitus observed in the treatment arm, balancing CV benefit against metabolic risk.

Fellow

Does the benefit of rosuvastatin in the JUPITER trial stem primarily from its anti-inflammatory properties (lowering hsCRP) or from driving LDL cholesterol to extremely low levels? How does this dual reduction alter secondary prevention strategies in modern cardiology?

Key Response

JUPITER sparked massive debate on whether statins benefits in this population are due to pleiotropic anti-inflammatory effects or simply the lower is better LDL hypothesis. Subsequent analyses showed patients achieving both low LDL and low hsCRP had the best outcomes, supporting dual-target strategies in lipidology and preventive cardiology.

Attending

The JUPITER trial was stopped early at 1.9 years due to a clear benefit in the primary endpoint, yielding a dramatic relative risk reduction. How should an attending physician frame the absolute risk reduction and the implications of early trial termination when counseling an otherwise healthy patient about lifelong therapy?

Key Response

While the relative risk reduction was 44 percent, the absolute risk reduction was small (roughly 1.2 percent over 1.9 years), resulting in a high Number Needed to Treat (NNT) for a primary prevention population. Early termination can exaggerate treatment effects. Attendings must balance impressive relative statistics with realistic absolute benefits to facilitate true shared decision-making.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The Data and Safety Monitoring Board halted JUPITER early after a median follow-up of 1.9 years. What are the statistical risks of early termination for benefit (truncation bias), and how might this have affected the effect size estimates for both cardiovascular outcomes and long-term adverse events like incident diabetes?

Key Response

Stopping a trial early for benefit often overestimates the true treatment effect (random high) and limits the statistical power to detect longer-term adverse events, such as incident diabetes or myopathy. PhD researchers must recognize that early stopping compromises the precision of the point estimates and the comprehensive safety profile.

Journal Editor

As an editor evaluating the JUPITER manuscript, how do you critically assess the use of a combined primary endpoint that includes hospitalization for unstable angina alongside hard outcomes like death and MI, particularly in a trial funded by the drugs manufacturer?

Key Response

Composite endpoints increase statistical power but can be driven by softer, more subjective outcomes like hospitalization for unstable angina. A tough reviewer would scrutinize whether the robust relative risk reduction holds true for hard endpoints alone and look for potential bias in endpoint adjudication, especially given the sponsors involvement.

Guideline Committee

How did the findings of the JUPITER trial directly influence the ACC/AHA cholesterol management guidelines regarding the use of hsCRP as a risk-enhancing factor, and what is the current strength of recommendation for using hsCRP to guide statin initiation in intermediate-risk patients?

Key Response

JUPITER provided the foundational evidence for incorporating hsCRP as a risk enhancer in the 2018 AHA/ACC guidelines. For patients at intermediate ASCVD risk (7.5 to 20 percent 10-year risk) where the decision for statin therapy is uncertain, an hsCRP greater than or equal to 2.0 mg/L is a Class IIa recommendation to favor initiating statin therapy, directly translating JUPITERs inclusion criteria into practice.

Clinical Landscape

Noteworthy Related Trials

1998

AFCAPS/TexCAPS

n = 6,605 · JAMA

Tested

Lovastatin 20-40 mg daily

Population

Adults with average cholesterol and low HDL without clinical ASCVD

Comparator

Placebo

Endpoint

First acute major coronary event

Key result: Lovastatin significantly reduced the risk for the first acute major coronary event in a population with average total cholesterol and LDL-C.

2016

HOPE-3 Trial

n = 12,705 · NEJM

Tested

Rosuvastatin 10 mg daily

Population

Intermediate-risk patients without cardiovascular disease

Comparator

Placebo

Endpoint

Composite of cardiovascular death, nonfatal MI, or nonfatal stroke

Key result: Rosuvastatin therapy resulted in a significantly lower risk of cardiovascular events than placebo.

2017

CANTOS Trial

n = 10,061 · NEJM

Tested

Canakinumab (IL-1beta inhibitor)

Population

Patients with prior MI and elevated hsCRP

Comparator

Placebo

Endpoint

Nonfatal MI, nonfatal stroke, or cardiovascular death

Key result: Antiinflammatory therapy with canakinumab led to a significantly lower rate of recurrent cardiovascular events independent of lipid lowering.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis